NCT00589862

Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Creighton University · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

It is recommended that patients who have drug-eluting stents placed in their coronary arteries take aspirin and Plavix (Clopidogrel) for at least a year. Patients who stop taking these antiplatelet drugs or who have resistance to the antiplatelet effects of these drugs are at a higher risk of clots occurring inside the stents which may result in a heart attack. At the present time, it is unknown if increasing the doses of the antiplatelet agents is effective in overcoming this resistance. The purpose of this project is to identify patients with antiplatelet drug resistance and to test whether an increase in the Plavix (Clopidogrel) dose overcomes antiplatelet drug resistance.

Conditions

• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	Plavix (Clopidogrel)	150 mg tablet of Plavix (Clopidogrel) per day for 12 months if resistance is identified

Timeline

• Start date: 2007-10-01
• Primary completion: 2008-07-01
• Completion: 2008-07-01
• First posted: 2008-01-10
• Last updated: 2015-11-30

Locations

1 site across 1 country: United States